[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341522-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341522-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","review-of-the-cost-effectiveness-of-surveillance-for-hereditary-pancreatic-cancer","Review of the cost-effectiveness of surveillance for hereditary pancreatic cancer","","Individuals with hereditary pancreatic cancer risk include high-risk individuals with germline genetic susceptibility to pancreatic cancer and/or strong family history. Prior studies indicate surveillance can downstage diagnoses and extend survival, yet the optimal strategy is unclear regarding modalities, surveillance intervals, and eligible subgroups. Cost-effectiveness analysis can compare costs, health benefits, and harms across strategies. This review summarizes evidence for hereditary pancreatic cancer surveillance and includes comparable analyses in new-onset diabetes as a high-risk reference group.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/review-of-the-cost-effectiveness-of-surveillance-for-hereditary-pancreatic-cancer/341522/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/review-of-the-cost-effectiveness-of-surveillance-for-hereditary-pancreatic-cancer/341522.png","ImageObject",300,407,{"name":42,"@type":43},"Oliver","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What patient groups are considered at high risk for hereditary pancreatic cancer in this review?","Question",{"text":63,"@type":64},"The review focuses on high-risk individuals with germline genetic susceptibility and/or a strong family history of pancreatic cancer, and it also compares with new-onset diabetes as a high-risk sporadic group.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why is cost-effectiveness important for pancreatic cancer surveillance strategies?",{"text":68,"@type":64},"Surveillance strategies involve trade-offs between health benefits and surveillance costs and potential harms, so cost-effectiveness analysis helps compare alternative approaches beyond clinical outcomes alone.",{"name":70,"@type":61,"acceptedAnswer":71},"What remains uncertain about surveillance for high-risk individuals?",{"text":72,"@type":64},"Key uncertainties include which imaging modalities to use, when to start and stop surveillance, and how frequently surveillance should be performed, along with which subgroups should undergo surveillance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341522,1791044876,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Familial Cancer (2024) 23:351–360  \n[https://doi.org/10.1007/s10689-024-00392-1](https://doi.org/10.1007/s10689-024-00392-1)  \nREVIEW  \nReview of the cost-effectiveness of surveillance for hereditary pancreatic cancer  \nLouise Wang1,2,3 · Rachel Levinson1 · Catherine Mezzacappa1 · Bryson W. Katona3  \nReceived: 1 December 2023 / Accepted: 16 April 2024 / Published online: 25 May 2024 © The Author(s) 2024  \nAbstract  \nIndividuals with hereditary pancreatic cancer risk include high risk individuals (HRIs) with germline genetic susceptibility to pancreatic cancer (PC) and/or a strong family history of PC. Previously, studies have shown that PC surveillance in HRIs can downstage PC diagnosis and extend survival leading to pancreatic surveillance being recommended for certain HRIs. However, the optimal surveillance strategy remains uncertain, including which modalities should be used for surveillance, how frequently should surveillance be performed, and which sub-groups of HRIs should undergo surveillance. Additionally, in the ideal world PC surveillance should also be cost-effective. Cost-effectiveness analysis is a valuable tool that can consider the costs, potential health benefits, and risks among various PC surveillance strategies. In this review, we summarize the cost-effectiveness of various PC surveillance strategies for HRIs for hereditary pancreatic cancer and provide potential avenues for future work in this field. Additionally, we include cost-effectiveness studies among individuals with new-onset diabetes (NoD), a high-risk group for sporadic PC, as a comparison.  \nGraphical Abstract  \nKeywords Hereditary pancreatic cancer · Pancreatic surveillance · Germline genetic risk · MRI · Endoscopic ultrasound · New-onset diabetes · Cost-effectiveness  \n􀀍 Bryson W. Katona [bryson.katona@pennmedicine.upenn.edu](bryson.katona@pennmedicine.upenn.edu)  \n1 Section of Digestive Diseases, Yale School of Medicine, New Haven, CT, USA  \n2 VA Connecticut Healthcare System, West Haven, CT, USA  \n3 Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, 3400 Civic Center Blvd. 751 South Pavilion, Philadelphia, PA 19104, USA  \nIntroduction  \nPancreatic cancer (PC) is the third leading cause of cancer death in the United States [1] . The majority of PC is metastatic at the time of diagnosis with poor survival (5-year survival rate: 3.2%) [2] . In contrast, PC diagnosed at local stages can often be treated surgically, resulting in improved survival (5-year survival rate: 44.3%) [2] . In fact, the most localized stage IA PC has a 5-year survival of over 80%[3], demonstrating how it is crucial to focus efforts on identifying PC at earlier stages to prevent PC-related deaths.  \nApproximately 10% of PC is hereditary due to either known germline genetic susceptibility and/or family history of PC. Genes associated with increased PC risk include hereditary breast cancer genes (BRCA1, BRCA2, ATM, and PALB2), CDKN2A (familial atypical multiple molemelanoma syndrome - FAMMM), Lynch syndrome genes (MLH1, MSH2/EPCAM, MSH6), STK11 (Peutz-Jeghers syndrome), TP53 (Li-Fraumeni syndrome), and hereditary pancreatitis genes such as PRSS1 [4] . Additionally thereis increased risk amongst families with familial pancreatic cancer (FPC), in which there are at least two relatives with PC who are directly related to one another, with the proband being a first-degree relative of one of the affected individuals, without a known pathogenic germline variant (PGV) ina PC risk gene. FPC may confer a lifetime PC risk estimate of up to 20–40% depending on the number of affected firstdegree relatives [4] . In contrast, 90% of PC is considered sporadic, arising in the absence of both a known genetic predisposition and a strong family history of PC. High-risk  \nsporadic groups include individuals with new-onset diabetes (NoD) diagnosed after age 50. The NoD in this cohort is thought to be a subclinical sign of existing PC and this risk","cbCaip7ExxclWvyB","https://ap.wps.com/l/cbCaip7ExxclWvyB","pdf",1429206,"English","# Introduction\n## Cost-effectiveness analyses","[{\"question\":\"What patient groups are considered at high risk for hereditary pancreatic cancer in this review?\",\"answer\":\"The review focuses on high-risk individuals with germline genetic susceptibility and/or a strong family history of pancreatic cancer, and it also compares with new-onset diabetes as a high-risk sporadic group.\"},{\"question\":\"Why is cost-effectiveness important for pancreatic cancer surveillance strategies?\",\"answer\":\"Surveillance strategies involve trade-offs between health benefits and surveillance costs and potential harms, so cost-effectiveness analysis helps compare alternative approaches beyond clinical outcomes alone.\"},{\"question\":\"What remains uncertain about surveillance for high-risk individuals?\",\"answer\":\"Key uncertainties include which imaging modalities to use, when to start and stop surveillance, and how frequently surveillance should be performed, along with which subgroups should undergo surveillance.\"}]","Review of the cost-effectiveness of surveillance for hereditary pancreatic cancer | PDF",1790042353,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4133681e3e43ea20622f3cb0f854d30a.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/06ba31a09d6af43065714dc12f05cc4b.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c3da708178fa45f0994c0c74147a77d5.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/865e82e5498895ed369c1d9a3c5f3cee.webp",980,1301]